<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521193</url>
  </required_header>
  <id_info>
    <org_study_id>CCM769</org_study_id>
    <nct_id>NCT03521193</nct_id>
  </id_info>
  <brief_title>pLatelEts And MigRaine iN patEnt foRamen Ovale</brief_title>
  <acronym>LEARNER</acronym>
  <official_title>Migraine in Patients Undergoing PFO (Patent Foramen Ovale) Closure: Evaluation of a Platelet-associated Pathophysiologic Linking Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a common, chronic neurovascular disorder characterized by attacks of severe&#xD;
      headache, autonomic nervous system dysfunction and, in some patients, aura, and disabling&#xD;
      neurological symptoms. Worldwide, migraine prevalence is as high as 18% in the general&#xD;
      population. Increased frequency of patent foramen ovale (PFO) in migraineurs was first&#xD;
      reported in 1998 in a case-control study. Since then, others have described a 60% prevalence&#xD;
      of PFO in patients suffering from migraine with aura. The presence of a right-to-left shunt&#xD;
      (RLS) is thought to be a potent trigger of migraine attacks, although the mechanism is&#xD;
      unknown. Moreover, PFO closure has correlated with improved migraine symptoms in several&#xD;
      retrospective uncontrolled studies. The aim of this single-center, prospective study is to&#xD;
      assess the impact of PFO closure on migraine attacks over time together with evaluation of&#xD;
      potential predictive risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study will evaluate the results of approximately 100 subjects from a single center study&#xD;
      registered in this trial. Subjects who experienced transient ischemic attack (TIA) or stroke&#xD;
      with a clinical indication to PFO closure and symptomatic for migraine with/o aura are&#xD;
      considered for a migraine score analysis at baseline before PFO closure and during the&#xD;
      subsequent follow-up (FU) at 6 and 12-months, together with lab evaluation for platelet&#xD;
      reactivity tests (P selectin, Thromboxane B2), Prostaglandin E1 and 2 (PGE1, PGE2),&#xD;
      serotonin, cytokines and prostaglandin PGE1 urinary metabolite run under aspirin therapy.&#xD;
&#xD;
      The research questions are as follows:&#xD;
&#xD;
      Does the presence of a large PFO have any impact on migraine with aura?&#xD;
&#xD;
      Do migraineurs with aura and PFO have higher biomarkers of platelet activation than control&#xD;
      patients? and are they at higher risk of stroke and TIA recurrences based on high on&#xD;
      clopidogrel platelet reactivity?&#xD;
&#xD;
      What is the effect of PFO severity on monthly migraine frequency and aura frequency?&#xD;
&#xD;
      What is the result of PFO closure in migraineur patients with PFO? Do Migraine with aura&#xD;
      patients with large PFO have higher platelet activation and better migraine resolution after&#xD;
      PFO closure?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: patients treated with PFO closure Group 2: Healthy subjects on Aspirin therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Migraine Characteristics</measure>
    <time_frame>The outcome data were evaluated at 6-months and 12-months after PFO closure and compared to baseline</time_frame>
    <description>The evaluation in absolute numbers of patients fully responders, non-responders or with a moderate benefit on migraine symptoms after PFO Closure was performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Migraine Assessment by Anzola's Score</measure>
    <time_frame>Baseline, 6 months and 12-months after PFO closure</time_frame>
    <description>The change in migraine severity, incidence and duration with or without aura as measured by the Anzola's score (The score is the expression of the sum of each corresponding value referring to migraine duration, frequency and the presence or absence of aura). The minimum value was 2 and the maximum 9; the higher the value, worse is the migraine classification.&#xD;
Anzola's score: Duration 0=No pain 1=&lt;6 hours 2=6-12 hours 3=&gt;12 hours Frequency 0=No pain 1=1-4/month 2=5-9/month 3=&gt;10/month Aura 0=No aura&#xD;
1=Aura in â‰¥1 attack</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Activation</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Platelet poor plasma levels of P selectin and serum concentration of B2-thromboxane (TXB2). (Plasma levels of P-selectin: ng/ml; Serum TXB2: ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Tests</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Verify-now Platelet Reactivity Unit (PRU): measures the P2Y12 platelet receptor blockade and platelet response to aspirin by an arachidonic acid initiated reaction. Verify-Now P2Y12 (PRU): Cut off: 208;&#xD;
-Verify-Now Aspirin (Aspirin Reactivity Unit (ARU): Cut off: 550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes</measure>
    <time_frame>In hospital, six and 12 months follow-up</time_frame>
    <description>Absence of TIA and stroke recurrences after PFO closure and during the follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Platelet Aggregation, Spontaneous</condition>
  <condition>Migraine With Aura</condition>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Migraine evaluation in PFO patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up and these results compared to those of a control, group of healthy subjects treated with aspirin alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects on aspirin treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>12 healthy subjects on 100 mg aspirin daily will be compared to PFO patients in terms of platelet reactivity, serotonin and cytokines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>patent foramen ovale closure</intervention_name>
    <description>Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment</description>
    <arm_group_label>Migraine evaluation in PFO patients</arm_group_label>
    <other_name>Occlutech Figulla Flex II PFO device; aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years with more than 2 criteria:&#xD;
&#xD;
          -  Previous Stroke or TIA (transient ischemic attack)&#xD;
&#xD;
          -  positive MRI for ischemic events -&#xD;
&#xD;
          -  PFO with a baseline R-L shunt &gt; 10 microembolic signals (MES) and &gt; 20 MES&#xD;
             during/after Valsalva Manoeuver&#xD;
&#xD;
          -  Atrial septal aneurysm (ASA) or residual Chiari network or Eustachian Valve&#xD;
&#xD;
          -  positive Thrombophilic screening (MTHFR/prot C/Prot S)&#xD;
&#xD;
          -  Ability to sign the informed consent for the study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients older than 70 years&#xD;
&#xD;
          -  Paroxysmal Atrial fibrillation&#xD;
&#xD;
          -  Carotid, vertebral or basilar artery stenosis&gt; 50% on duplex imaging&#xD;
&#xD;
          -  Inadequate temporal bone windows (signals) for transcranial Doppler insonation&#xD;
&#xD;
          -  medication overuse headache&#xD;
&#xD;
          -  history of cognitive dysfunction, epilepsy, brain injury&#xD;
&#xD;
          -  use of continuous positive airway pressure (CPAP) within 6 months of study enrollment&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &lt; 30%&#xD;
&#xD;
          -  Moderate/severe mitral valve regurgitation&#xD;
&#xD;
          -  Known Allergy to aspirin&#xD;
&#xD;
          -  Known allergy to nickel&#xD;
&#xD;
          -  Severe chronic kidney disease (GFR &lt; 30 ml/min)&#xD;
&#xD;
          -  Beck depression inventory score &gt; or= 29&#xD;
&#xD;
          -  State-trait anxiety inventory score exceeding cut-off for are and sex&#xD;
&#xD;
        Keywords: PFO, migraine, migraine with aura, aura, platelets&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Trabattoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino, IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>July 27, 2021</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Daniela Trabattoni</investigator_full_name>
    <investigator_title>MD, FACC</investigator_title>
  </responsible_party>
  <keyword>Migraine;</keyword>
  <keyword>PFO</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>aura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03521193/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at Centro Cardiologico Monzino, Milan, Italy between February 2018 and April 2020</recruitment_details>
      <pre_assignment_details>After screening of 93 consecutive PFO patients suffering from migraine 15 were excluded due to unwillingness to sign the informed consent, absence of patent PFO at the invasive evaluation, intolerance to antiplatelet therapy. Finally, 78 pts were enrolled in the study and assigned to the PFO Arm; another arm included 12healthy subjects on Aspirin treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PFO and Migraine Pts</title>
          <description>93 consecutive patients addressed to PFO closure and suffering from migraine with aura were prospectively screened. 78 patients were enrolled in the study (T0)</description>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects on Aspirin</title>
          <description>12 healthy subjects on ASA treatment were the control group for phase 2 study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78">enrolled on the PFO closure hospitalization</participants>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62">8 pts refused to continue the study; 8 patients were non compliant to ASA treatment</participants>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliant to ASA treatment</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Final evaluation was performed on 62 patients. This group was compared to a control group (12 healthy subjects) on aspirin. Comparison was performed before PFO closure (T0) and during follow-up (T1) in terms of serotonin, platelet aggregation and activation markers and cell-associated procoagulant effect</population>
      <group_list>
        <group group_id="B1">
          <title>PFO Patients Enrolled</title>
          <description>We enrolled consecutive patients who met the inclusion criteria, symptomatic for migraine alone and Migraine with aura (MHA) patients.&#xD;
The leading indication to PFO closure was a previous TIA or stroke in 37 patients while an off-label indication was offered to 25 patients. These pts underwent PFO closure with the Occlutech Figulla device and treated with dual antiplatelet therapy (Aspirin 100 mg/day + Clopidogrel 75 mg/day), followed by aspirin 100 mg/day alone.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Subjects</title>
          <description>Healthy subjects on aspirin treatment by at least 15 days were the comparative group for platelet aggregation markers and activation markers, platelet procoagulant, circulating serotonin and cell-associated procoagulant potential</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="12"/>
                    <measurement group_id="B2" value="41" spread="10"/>
                    <measurement group_id="B3" value="40.8" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine</title>
          <description>number of participants sffering from Migraine alone (MA)</description>
          <units>Migraine</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine with aura (MHA)</title>
          <description>Number of patients suffering from Migraine with aura (MHA)</description>
          <units>Migraine with aura</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients finally evaluated</title>
          <population>8 patients refused to continue the study ; 8 patients were not compliant to aspirin treatment, therefore final analysis was performed on 62 patients</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="62"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Migraine Characteristics</title>
        <description>The evaluation in absolute numbers of patients fully responders, non-responders or with a moderate benefit on migraine symptoms after PFO Closure was performed</description>
        <time_frame>The outcome data were evaluated at 6-months and 12-months after PFO closure and compared to baseline</time_frame>
        <population>Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
        <group_list>
          <group group_id="O1">
            <title>Migraine Assessment After PFO Closure</title>
            <description>Migraine symptoms evaluation after PFO closure</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Migraine Characteristics</title>
          <description>The evaluation in absolute numbers of patients fully responders, non-responders or with a moderate benefit on migraine symptoms after PFO Closure was performed</description>
          <population>Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Migraine : Complete Migraine Resolution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine : Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine Symptoms improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Migraine Assessment by Anzola's Score</title>
        <description>The change in migraine severity, incidence and duration with or without aura as measured by the Anzola's score (The score is the expression of the sum of each corresponding value referring to migraine duration, frequency and the presence or absence of aura). The minimum value was 2 and the maximum 9; the higher the value, worse is the migraine classification.&#xD;
Anzola's score: Duration 0=No pain 1=&lt;6 hours 2=6-12 hours 3=&gt;12 hours Frequency 0=No pain 1=1-4/month 2=5-9/month 3=&gt;10/month Aura 0=No aura&#xD;
1=Aura in â‰¥1 attack</description>
        <time_frame>Baseline, 6 months and 12-months after PFO closure</time_frame>
        <population>Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Patients Enrolled</title>
            <description>We enrolled consecutive patients who met the inclusion criteria, symptomatic for migraine alone and Migraine with aura (MHA) patients. Eight patients refused to continue the study and eight were non-compliant to antiplatelet therapy during the follow-up. .&#xD;
The leading indication to PFO closure was a previous TIA or stroke in 37 patients while an off-label indication was offered to 25 patients. These pts underwent PFO closure with the Occlutech Figulla device and treated with dual antiplatelet therapy (Aspirin 100 mg/day + Clopidogrel 75 mg/day), followed by aspirin 100 mg/day alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Assessment by Anzola's Score</title>
          <description>The change in migraine severity, incidence and duration with or without aura as measured by the Anzola's score (The score is the expression of the sum of each corresponding value referring to migraine duration, frequency and the presence or absence of aura). The minimum value was 2 and the maximum 9; the higher the value, worse is the migraine classification.&#xD;
Anzola's score: Duration 0=No pain 1=&lt;6 hours 2=6-12 hours 3=&gt;12 hours Frequency 0=No pain 1=1-4/month 2=5-9/month 3=&gt;10/month Aura 0=No aura&#xD;
1=Aura in â‰¥1 attack</description>
          <population>Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anzola's score @Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anzola's score@6-mos post PFO Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anzola's score @12-mos post PFO closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Activation</title>
        <description>Platelet poor plasma levels of P selectin and serum concentration of B2-thromboxane (TXB2). (Plasma levels of P-selectin: ng/ml; Serum TXB2: ng/ml)</description>
        <time_frame>baseline and 6 months</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Tests</title>
        <description>Verify-now Platelet Reactivity Unit (PRU): measures the P2Y12 platelet receptor blockade and platelet response to aspirin by an arachidonic acid initiated reaction. Verify-Now P2Y12 (PRU): Cut off: 208;&#xD;
-Verify-Now Aspirin (Aspirin Reactivity Unit (ARU): Cut off: 550</description>
        <time_frame>baseline and 6 months</time_frame>
        <posting_date>02/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcomes</title>
        <description>Absence of TIA and stroke recurrences after PFO closure and during the follow-up</description>
        <time_frame>In hospital, six and 12 months follow-up</time_frame>
        <population>Clinical evaluation of neurologic recurrences or death was performed during in-hospital stay and subsequent follow-up; Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Patients Enrolled</title>
            <description>We enrolled 62 consecutive PFO patients suffering from migraine, addressed to PFO closure. The leading indication to PFO closure was a previous TIA or stroke in 37 patients while an off-label indication was offered to 25 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcomes</title>
          <description>Absence of TIA and stroke recurrences after PFO closure and during the follow-up</description>
          <population>Clinical evaluation of neurologic recurrences or death was performed during in-hospital stay and subsequent follow-up; Analysis performed only in PFO Group patients as not applicable to the control Healthy subjects group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In -hospital vascular complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>device malpositioning/embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIA/stroke post PFO Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent TIAs /stroke @6 months FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent TIAs /stroke @12 months FU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>in -hospital, 6 months and 1 year</time_frame>
      <desc>Adverse event definitions were the same adopted by clinicaltrials.gov ; EVENTS WERE COLLECTED during clinical visit in-hospital and at follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>Migraine Evaluation in PFO Patients</title>
          <description>Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Clinical evaluation performed during in-hospital stay, at 6- and 12-months follow-up</description>
        </group>
        <group group_id="E2">
          <title>Healthy Subjects</title>
          <description>control Healthy subjects group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>MHA may have a multifactorial etiology. The role of oxidative stress appears consistent and corroborated by the in vitro data. The effect of serotonin and oxidative stress was tested on platelets from healthy subjects and not from pts because the Sars-Cov-2 pandemic imposed restrictions on pts enrolment. Finally, the thrombin generation capacity of platelets and MVs were included after the study started to support the pro-coagulant phenotype evidenced by ad interim flow cytometry data analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trials' Office Chief</name_or_title>
      <organization>Centro Cardiologico Monzino, IRCCS</organization>
      <phone>+390258002 ext 675</phone>
      <email>alessandra.terragni@ccfm.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

